- Report
- February 2026
- 250 Pages
Global
From €4147EUR$4,490USD£3,469GBP
- Report
- September 2026
- 199 Pages
Global
From €3274EUR$3,545USD£2,739GBP
€3638EUR$3,939USD£3,043GBP
- Report
- September 2026
- 183 Pages
Global
From €3274EUR$3,545USD£2,739GBP
€3638EUR$3,939USD£3,043GBP
- Report
- September 2026
- 186 Pages
Global
From €3274EUR$3,545USD£2,739GBP
€3638EUR$3,939USD£3,043GBP
- Report
- September 2026
- 184 Pages
Global
From €3274EUR$3,545USD£2,739GBP
€3638EUR$3,939USD£3,043GBP
- Report
- September 2026
- 187 Pages
Global
From €3274EUR$3,545USD£2,739GBP
€3638EUR$3,939USD£3,043GBP
- Report
- September 2026
- 194 Pages
Global
From €3274EUR$3,545USD£2,739GBP
€3638EUR$3,939USD£3,043GBP
- Report
- September 2026
- 192 Pages
Global
From €3274EUR$3,545USD£2,739GBP
€3638EUR$3,939USD£3,043GBP
- Report
- January 2026
- 182 Pages
Global
From €3274EUR$3,545USD£2,739GBP
€3638EUR$3,939USD£3,043GBP
- Report
- January 2026
- 183 Pages
Global
From €3274EUR$3,545USD£2,739GBP
€3638EUR$3,939USD£3,043GBP
- Report
- October 2026
- 488 Pages
Global
From €5403EUR$5,850USD£4,519GBP
- Report
- October 2026
- 394 Pages
Global
From €5403EUR$5,850USD£4,519GBP
- Report
- February 2026
- 250 Pages
Global
From €4147EUR$4,490USD£3,469GBP
- Report
- May 2026
- 185 Pages
Global
From €4156EUR$4,500USD£3,476GBP
- Report
- October 2026
- 274 Pages
Global
From €5403EUR$5,850USD£4,519GBP
- Report
- July 2026
- 400 Pages
Global
From €7380EUR$7,990USD£6,173GBP
- Report
- July 2026
- 193 Pages
Global
From €7380EUR$7,990USD£6,173GBP
- Report
- July 2026
- 295 Pages
Global
From €7380EUR$7,990USD£6,173GBP
- Report
- May 2026
- 30 Pages
Global
From €2540EUR$2,750USD£2,124GBP
- Report
- April 2026
- 225 Pages
Global
From €7380EUR$7,990USD£6,173GBP

Tofacitinib is a drug used to treat immune disorders, such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It is a Janus kinase (JAK) inhibitor, which works by blocking the action of certain enzymes that are involved in the body's inflammatory response. Tofacitinib is taken orally, usually twice daily. It is available in both tablet and solution form.
Tofacitinib is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2012. It is the first JAK inhibitor to be approved for the treatment of immune disorders. Since its approval, it has become a popular treatment option for many patients.
The market for Tofacitinib is highly competitive, with several companies offering the drug. These include Pfizer, Novartis, AbbVie, and Merck. Each company has its own formulation of the drug, and they compete on price, efficacy, and safety. Show Less Read more